LeMaitre Vascular, Inc.·Healthcare

BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025, at 2:15 PM EDT.

Shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average

2,625 shares were exercised and sold on March 11, 2026, generating a transaction value of approximately $285,000 at a weighted average sale price of around $108.50 per share. This disposition represented 28.22% of Kamke's direct holdings prior to the transaction, reducing direct ownership to 6,677 shares.

An executive of LeMaitre Vascular reported selling 2,625 shares of the company for $285,000 on March 11, 2026. The sale represented 28.22% of Kamke's direct common stock holdings, reducing the position to 6,677 shares.

Congress Asset Management Co. boosted its stake in LeMaitre Vascular, Inc. (NASDAQ: LMAT) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 732,331 shares of the medical instruments supplier's stock after acquiring an additional 40,065 shares during the quarter. Congress Asset Management Co.

The market has been going through a visible rotation. Dividend payers have been outperforming so far this year as investors rotate from large-cap AI names into “old economy” stocks. If you own software names that depend on pricing power through expensive licensing, you need to revisit your thesis. Higher energy prices would ultimately filter through to consumer and producer prices, leaving central banks scrambling to reassess their interest rate trajectory.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Healthcare
Medical - Instruments & Supplies
651
2006-10-19
0.67